Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06609876
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-20
Brief Title:
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Thermal Ablation Combined With Low-dose Donafinib for Early Recurrent Hepatocellular Carcinoma a Multicenter Prospective Study
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria
Detailed Description:
Thermal ablation is available as the major curative treatments for early-stage recurrent HCC Donafenib was inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma No study has evaluated low-dose donafenib as adjuvant therapy after thermal ablation There needs further investigation to explore the efficacy and safety of the combination treatment Thus the investigators carried out this prospective randomized open-label phase II trial study to find out it
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None